Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Capital Expenditures: 2023-2025

Historic Capital Expenditures for Compass Therapeutics (CMPX) over the last 1 years, with Sep 2025 value amounting to $7,000.

  • Compass Therapeutics' Capital Expenditures fell 84.09% to $7,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $78,000, marking a year-over-year increase of 5.41%. This contributed to the annual value of $44,000 for FY2024, which is 46.67% up from last year.
  • Compass Therapeutics' Capital Expenditures amounted to $7,000 in Q3 2025, which was down 61.11% from $18,000 recorded in Q1 2025.
  • In the past 5 years, Compass Therapeutics' Capital Expenditures ranged from a high of $44,000 in Q3 2024 and a low of $7,000 during Q3 2025.
  • Its 3-year average for Capital Expenditures is $16,500, with a median of $10,500 in 2023.
  • In the last 5 years, Compass Therapeutics' Capital Expenditures spiked by 340.00% in 2024 and then crashed by 84.09% in 2025.
  • Over the past 3 years, Compass Therapeutics' Capital Expenditures (Quarterly) stood at $9,000 in 2023, then surged by 340.00% to $44,000 in 2024, then tumbled by 84.09% to $7,000 in 2025.
  • Its last three reported values are $7,000 in Q3 2025, $18,000 for Q1 2025, and $44,000 during Q3 2024.